Business Description
Bafna Pharmaceuticals Ltd
ISIN : INE878I01022
Total Employee Number:
406Compare
Compare
Traded in other countries / regions
532989.India IPO Date
2012-11-12Description
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | 1.81 | |||||
Interest Coverage | 2.7 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.9 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.3 | |||||
3-Year EBITDA Growth Rate | 3.3 | |||||
3-Year EPS without NRI Growth Rate | -0.6 | |||||
3-Year FCF Growth Rate | -42.9 | |||||
3-Year Book Growth Rate | 9.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.42 | |||||
9-Day RSI | 72.79 | |||||
14-Day RSI | 68.95 | |||||
3-1 Month Momentum % | 15.39 | |||||
6-1 Month Momentum % | -21.09 | |||||
12-1 Month Momentum % | 74.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.57 | |||||
Quick Ratio | 1.06 | |||||
Cash Ratio | 0.07 | |||||
Days Inventory | 104.46 | |||||
Days Sales Outstanding | 94.24 | |||||
Days Payable | 104.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -2.43 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 31.96 | |||||
Operating Margin % | 6.56 | |||||
Net Margin % | 7.37 | |||||
EBITDA Margin % | 13.75 | |||||
FCF Margin % | -6.33 | |||||
OCF Margin % | 10.21 | |||||
ROE % | 12.23 | |||||
ROA % | 6.81 | |||||
ROIC % | 7.64 | |||||
3-Year ROIIC % | -3.86 | |||||
ROC (Joel Greenblatt) % | 12 | |||||
ROCE % | 13.2 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 42.32 | |||||
PE Ratio without NRI | 42.32 | |||||
Shiller PE Ratio | 48.15 | |||||
Price-to-Owner-Earnings | 2756.94 | |||||
PEG Ratio | 4.23 | |||||
PS Ratio | 3.12 | |||||
PB Ratio | 4.88 | |||||
Price-to-Tangible-Book | 4.88 | |||||
Price-to-Operating-Cash-Flow | 30.56 | |||||
EV-to-EBIT | 34.4 | |||||
EV-to-EBITDA | 24.31 | |||||
EV-to-Revenue | 3.34 | |||||
EV-to-FCF | -52.8 | |||||
Price-to-GF-Value | 2.12 | |||||
Price-to-Peter-Lynch-Fair-Value | 6.56 | |||||
Price-to-Graham-Number | 3.03 | |||||
| Price-to-Net-Current-Asset-Value | 45.7 | |||||
Earnings Yield (Greenblatt) % | 2.91 | |||||
FCF Yield % | -2.03 | |||||
Forward Rate of Return (Yacktman) % | 8.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bafna Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,506.173 | ||
| EPS (TTM) (₹) | 4.69 | ||
| Beta | 0.2425 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.45 | ||
| Volatility % | 83.37 | ||
| 14-Day RSI | 68.95 | ||
| 14-Day ATR (₹) | 9.979829 | ||
| 20-Day SMA (₹) | 164.093 | ||
| 12-1 Month Momentum % | 74.74 | ||
| 52-Week Range (₹) | 77 - 213.36 | ||
| Shares Outstanding (Mil) | 23.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bafna Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bafna Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2019-08-26 | 3.55 (-4.05%) |
Show
Entries
Bafna Pharmaceuticals Ltd Frequently Asked Questions
What is Bafna Pharmaceuticals Ltd(NSE:BAFNAPH)'s stock price today?
The current price of NSE:BAFNAPH is ₹194.68. The 52 week high of NSE:BAFNAPH is ₹213.36 and 52 week low is ₹77.00.
When is next earnings date of Bafna Pharmaceuticals Ltd(NSE:BAFNAPH)?
The next earnings date of Bafna Pharmaceuticals Ltd(NSE:BAFNAPH) is .
Does Bafna Pharmaceuticals Ltd(NSE:BAFNAPH) pay dividends? If so, how much?
Bafna Pharmaceuticals Ltd(NSE:BAFNAPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Bafna Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers